References:
1Global, regional, and national burden of stroke, 1990-2016: a systematic analysisfor the Global Burden of Disease Study 2016. Global, regional, and national burden of stroke, 1990-2016: a systematic analysisfor the Global Burden of Disease Study 2016. The Lancet. Neurology. 2019;18(5):439-58. 'doi:'10.1016/S1474-4422(19)30034-1.
2Wardlaw JM, Sandercock PAG, Berge E. Thrombolytic therapy with recombinant tissue plasminogen activator for acuteischemic stroke: where do we go from here? A cumulative meta-analysis. STROKE. 2003;34(6):1437-42
3Henderson SJ, Weitz JI, Kim PY. Fibrinolysis: strategies to enhance the treatment of acute ischemic stroke. Journal of thrombosis and haemostasis : JTH. 2018;16(10):1932-40. 'doi:'10.1111/jth.14215.
4Ouk T, Potey C, Gautier S, Bastide M, Deplanque D, Staels B et al. PPARs: a potential target for a disease-modifying strategy in stroke. CURR DRUG TARGETS. 2013;14(7):752-67
5Pereira MP, Hurtado O, Cardenas A, Bosca L, Castillo J, Davalos A et al. Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 cause potentneuroprotection after experimental stroke through noncompletely overlappingmechanisms. 2006. p. 218-29.
6Lin T, Cheung W, Wu J, Chen J, Lin H, Chen J et al. 15d-prostaglandin J2 protects brain from ischemia-reperfusion injury. Arteriosclerosis, thrombosis, and vascular biology. 2006;26(3):481-7
7Ji S, Kronenberg G, Balkaya M, Farber K, Gertz K, Kettenmann H et al. Acute neuroprotection by pioglitazone after mild brain ischemia without effect onlong-term outcome. EXP NEUROL. 2009;216(2):321-8. 'doi:'10.1016/j.expneurol.2008.12.007.
8Kaundal RK, Sharma SS. GW1929: a nonthiazolidinedione PPARgamma agonist, ameliorates neurological damagein global cerebral ischemic-reperfusion injury through reduction in inflammation and DNA fragmentation. BEHAV BRAIN RES. 2011;216(2):606-12. 'doi:'10.1016/j.bbr.2010.09.001.
9Culman J, Nguyen-Ngoc M, Glatz T, Gohlke P, Herdegen T, Zhao Y. Treatment of rats with pioglitazone in the reperfusion phase of focal cerebralischemia: a preclinical stroke trial. EXP NEUROL. 2012;238(2):243-53. 'doi:'10.1016/j.expneurol.2012.09.003.
10Zhao Y, Song J, Ma X, Zhang B, Li D, Pang H. Rosiglitazone ameliorates diffuse axonal injury by reducing loss of tau andup-regulating caveolin-1 expression. NEURAL REGEN RES. 2016;11(6):944-50. 'doi:'10.4103/1673-5374.184493.
11Zhao Y, Wei X, Song J, Zhang M, Huang T, Qin J. Peroxisome Proliferator-Activated Receptor gamma Agonist Rosiglitazone ProtectsBlood-Brain Barrier Integrity Following Diffuse Axonal Injury by Decreasing theLevels of Inflammatory Mediators Through a Caveolin-1-Dependent Pathway. INFLAMMATION. 2019;42(3):841-56. 'doi:'10.1007/s10753-018-0940-2.
12Huang Q, Zhong W, Hu Z, Tang X. A review of the role of cav-1 in neuropathology and neural recovery afterischemic stroke. J NEUROINFLAMM. 2018;15(1):348. 'doi:'10.1186/s12974-018-1387-y.
13Choi K, Kim H, Park M, Kim J, Kim J, Cho K et al. Regulation of Caveolin-1 Expression Determines Early Brain Edema AfterExperimental Focal Cerebral Ischemia. STROKE. 2016;47(5):1336-43. 'doi:'10.1161/STROKEAHA.116.013205.
14Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. STROKE. 1989;20(1):84-91
15Li W, Chen Z, Chin I, Chen Z, Dai H. The Role of VE-cadherin in Blood-brain Barrier Integrity Under Central NervousSystem Pathological Conditions. CURR NEUROPHARMACOL. 2018;16(9):1375-84. 'doi:'10.2174/1570159X16666180222164809.
16Neuhaus W, Piontek A, Protze J, Eichner M, Mahringer A, Subileau E et al. Reversible opening of the blood-brain barrier by claudin-5-binding variants ofClostridium perfringens enterotoxin's claudin-binding domain. BIOMATERIALS. 2018;161:129-43. 'doi:'10.1016/j.biomaterials.2018.01.028.
17Tang X, Zhong W, Tu Q, Ding B. NADPH oxidase mediates the expression of MMP-9 in cerebral tissue afterischemia-reperfusion damage. NEUROL RES. 2014;36(2):118-25. 'doi:'10.1179/1743132813Y.0000000266.
18Anderson RG. The caveolae membrane system. ANNU REV BIOCHEM. 1998;67:199-225
19Liu P, Rudick M, Anderson RGW. Multiple functions of caveolin-1. The Journal of biological chemistry. 2002;277(44):41295-8
20Nguyen KCT, Cho KA. Versatile Functions of Caveolin-1 in Aging-related Diseases. Chonnam medical journal. 2017;53(1):28-36. 'doi:'10.4068/cmj.2017.53.1.28.
21Ikezu T, Ueda H, Trapp BD, Nishiyama K, Sha JF, Volonte D et al. Affinity-purification and characterization of caveolins from the brain:differential expression of caveolin-1, -2, and -3 in brain endothelial andastroglial cell types. BRAIN RES. 1998;804(2):177-92
22Virgintino D, Robertson D, Errede M, Benagiano V, Tauer U, Roncali L et al. Expression of caveolin-1 in human brain microvessels. NEUROSCIENCE. 2002;115(1):145-52
23Stary CM, Tsutsumi YM, Patel PM, Head BP, Patel HH, Roth DM. Caveolins: targeting pro-survival signaling in the heart and brain. FRONT PHYSIOL. 2012;3:393. 'doi:'10.3389/fphys.2012.00393.
24Liu J, Wang LN. Peroxisome proliferator-activated receptor gamma agonists for preventing recurrent stroke and other vascular events in people with stroke or transient ischaemic attack. Cochrane Database Syst Rev. 2019;10:D10693. 'doi:'10.1002/14651858.CD010693.pub5.
25Li Y, Zhu Z, Lu B, Huang T, Zhang Y, Zhou N et al. Rosiglitazone ameliorates tissue plasminogen activator-induced brain hemorrhageafter stroke. CNS NEUROSCI THER. 2019;25(12):1343-52. 'doi:'10.1111/cns.13260.
26Villapol S. Roles of Peroxisome Proliferator-Activated Receptor Gamma on Brain and PeripheralInflammation. CELL MOL NEUROBIOL. 2018;38(1):121-32. 'doi:'10.1007/s10571-017-0554-5.
27Shao Z, Liu Z. Neuroinflammation and neuronal autophagic death were suppressed via Rosiglitazone treatment: New evidence on neuroprotection in a rat model of global cerebral ischemia. J NEUROL SCI. 2015;349(1-2):65-71. 'doi:'10.1016/j.jns.2014.12.027.
28Llaverias G, Vazquez-Carrera M, Sanchez RM, Noe V, Ciudad CJ, Laguna JC et al. Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through aPPAR-dependent mechanism. J LIPID RES. 2004;45(11):2015-24
29Tencer L, Burgermeister E, Ebert MP, Liscovitch M. Rosiglitazone induces caveolin-1 by PPARgamma-dependent and PPRE-independentmechanisms: the role of EGF receptor signaling and its effect on cancer cell drugresistance. ANTICANCER RES. 2008;28(2A):895-906
30Gu Y, Zheng G, Xu M, Li Y, Chen X, Zhu W et al. Caveolin-1 regulates nitric oxide-mediated matrix metalloproteinases activity andblood-brain barrier permeability in focal cerebral ischemia and reperfusioninjury. J NEUROCHEM. 2012;120(1):147-56. 'doi:'10.1111/j.1471-4159.2011.07542.x.
31Shen J, Ma S, Chan P, Lee W, Fung PC, Cheung RT et al. Nitric oxide down-regulates caveolin-1 expression in rat brains during focal cerebral ischemia and reperfusion injury. J NEUROCHEM. 2006;96(4):1078-89. 'doi:'10.1111/j.1471-4159.2005.03589.x.
32Bucci M, Gratton JP, Rudic RD, Acevedo L, Roviezzo F, Cirino G et al. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. NAT MED. 2000;6(12):1362-7. 'doi:'10.1038/82176.
33Sato Y, Sagami I, Shimizu T. Identification of caveolin-1-interacting sites in neuronal nitric-oxide synthase. Molecular mechanism for inhibition of NO formation. J BIOL CHEM. 2004;279(10):8827-36. 'doi:'10.1074/jbc.M310327200.
34Zhang S, Liu Y, Zhao Z, Xue Y. Effects of green tea polyphenols on caveolin-1 of microvessel fragments in ratswith cerebral ischemia. NEUROL RES. 2010;32(9):963-70. 'doi:'10.1179/016164110X12700393823570.
35Huang P, Zhou C, Qin-Hu, Liu Y, Hu B, Chang X et al. Cerebralcare Granule(R) attenuates blood-brain barrier disruption after middlecerebral artery occlusion in rats. EXP NEUROL. 2012;237(2):453-63. 'doi:'10.1016/j.expneurol.2012.07.017.
36Yang B, Xu J, Chang L, Miao Z, Heang D, Pu Y et al. Cystatin C improves blood-brain barrier integrity after ischemic brain injury in mice. J NEUROCHEM. 2019. 'doi:'10.1111/jnc.14894.